Cell 
Therapies+
  • All Cell Therapy Services
  • Plasmid Engineering
  • Cell Banking
  • TESSA® Technology
  • XOFLX® Cell Lines
  • Cell Line Development
  • Technology Transfer
  • Cell Therapy Process & Analytical Development
  • Cell Therapy GMP Manufacturing
Viral 
Vectors+
  • All Viral Vector Services
  • Plasmid Engineering
  • Cell Banking
  • TESSA® Technology
  • XOFLX® Cell Lines
  • Cell Line Development
  • Viral Vector Process Development
  • Viral Vector GMP Manufacturing
Biologics &
CGT Testing+
  • Minaris Advanced Testing
  • Testing Services+
    • Testing Services Overview
    • Analytical Development
    • Assay Transfer
    • Biosafety Testing
    • Cell Line Characterization
    • Lot Release
    • Potency
    • Stability
    • Viral Clearance
  • Testing by Modality
  • Minaris Advanced Testing Facilities
  • Minaris Advanced Testing Leadership
  • Minaris Advanced Testing History
  • Submit a Sample
Regulatory
& CMC+
  • Quality
  • Regulatory Support
Technologies
& Platforms+
  • Viral Vector Technologies
  • Cell Therapy Technologies
  • Testing Technologies+
    • AgentSCREEN™
    • Transmission Electron Microscopy (TEM)
About
Us+
  • The Minaris Story
  • Global Footprint for Local Manufacture
  • Leadership
  • News & Announcements
  • Events
  • Careers
Knowledge
Center
Contact Us

Enter a term to search

Minaris Enhancing lentiviral vector titre by limiting auto-transduction

December 11, 2025

By Jonny Clark

Stay Connected with Minaris

Want the lastest insights on cell and gene therapy manufacturing and testing? Subscribe to receive updates, news and resources directly from our team.

Follow us on LinkedIn to stay updated on industry insights, innovations and company news.

Contact Us

  • 400 Rouse Boulevard,
    Philadelphia, PA 19112
  • +1-215-218-7100

© 2026 Minaris Advanced Therapies, LLC. All Rights Reserved.

  • Terms of Use
  • Privacy Policy
  • Data Policy
  • Cookies Policy